Chapter 15 – Acromegaly

[1]  S. Melmed.  Pituitary Medicine From Discovery to Patient-Focused Outcomes. , 2016, The Journal of clinical endocrinology and metabolism.

[2]  J. Jørgensen,et al.  Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. , 2015, European journal of endocrinology.

[3]  C. Stratakis,et al.  Carney complex: an update. , 2015, European journal of endocrinology.

[4]  P. Chanson,et al.  Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study , 2015, European journal of endocrinology.

[5]  A. Tönjes,et al.  The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  J. Wass,et al.  60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly. , 2015, The Journal of endocrinology.

[7]  M. Gadelha,et al.  Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study , 2015, European journal of endocrinology.

[8]  J. Lupski,et al.  X-linked acrogigantism syndrome: clinical profile and therapeutic responses. , 2015, Endocrine-related cancer.

[9]  Zhezhen Jin,et al.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition , 2015, Pituitary.

[10]  S. Fjalldal,et al.  The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013 , 2015, Pituitary.

[11]  M. Bronstein,et al.  Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. , 2015, The Journal of clinical endocrinology and metabolism.

[12]  I. Floriani,et al.  Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. , 2015, The Journal of clinical endocrinology and metabolism.

[13]  P. Marzullo,et al.  Growth hormone deficiency in treated acromegaly , 2015, Trends in Endocrinology & Metabolism.

[14]  B. Glaser,et al.  Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. , 2015, The Journal of clinical endocrinology and metabolism.

[15]  A. Mamelak,et al.  A structural and functional acromegaly classification. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  C. Boguszewski,et al.  Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system , 2015, Pituitary.

[17]  S. Bergé,et al.  Three-dimensional facial analysis in acromegaly: a novel tool to quantify craniofacial characteristics after long-term remission , 2015, Pituitary.

[18]  J. Lupski,et al.  Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. , 2014, The New England journal of medicine.

[19]  R. Murray,et al.  Lanreotide autogel in acromegaly – a decade on , 2014, Expert opinion on pharmacotherapy.

[20]  M. Fleseriu,et al.  Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.

[21]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[22]  G. Vargas,et al.  Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  Eun Jig Lee,et al.  Clinical predictors of GH deficiency in surgically cured acromegalic patients. , 2014, European journal of endocrinology.

[24]  J. Honegger,et al.  Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. , 2014, The Journal of clinical endocrinology and metabolism.

[25]  M. Buchfelder,et al.  Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. , 2014, The Journal of clinical endocrinology and metabolism.

[26]  M. Korbonits,et al.  Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis. , 2014, The Journal of clinical endocrinology and metabolism.

[27]  M. Korbonits,et al.  Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. , 2014, The Journal of clinical endocrinology and metabolism.

[28]  P. Chanson,et al.  Expert consensus document: A consensus on the medical treatment of acromegaly , 2014, Nature Reviews Endocrinology.

[29]  S. Melmed,et al.  Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis , 2014, The Journal of clinical endocrinology and metabolism.

[30]  R. Mamluk,et al.  A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms , 2014, Pharmaceutical Research.

[31]  A. Czarnywojtek,et al.  Risk of Thyroid Nodular Disease and Thyroid Cancer in Patients with Acromegaly – Meta-Analysis and Systematic Review , 2014, PloS one.

[32]  P. Chanson,et al.  Acromegaly and McCune-Albright syndrome. , 2014, The Journal of clinical endocrinology and metabolism.

[33]  R. Clayton,et al.  A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. , 2014, The Journal of clinical endocrinology and metabolism.

[34]  J. Sheehan,et al.  Stereotactic radiosurgery for acromegaly. , 2014, The Journal of clinical endocrinology and metabolism.

[35]  M. Fleseriu,et al.  Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study , 2014, The Journal of clinical endocrinology and metabolism.

[36]  A. Tabarin,et al.  Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial , 2013, The Journal of clinical endocrinology and metabolism.

[37]  A. Barkan,et al.  Tamoxifen as a therapeutic agent in acromegaly , 2014, Pituitary.

[38]  S. Doi,et al.  Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies , 2014, Pituitary.

[39]  M. Fleseriu.  Insight into cardiovascular risk factors in patients with acromegaly , 2014, Endocrine.

[40]  S. Işık,et al.  Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. , 2013, Journal of neurosurgery.

[41]  Min-Seon Kim,et al.  Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. , 2013, Neurosurgery.

[42]  M. Fleseriu.  The role of combination medical therapy in acromegaly: hope for the nonresponsive patient , 2013, Current opinion in endocrinology, diabetes, and obesity.

[43]  E. Oldfield,et al.  Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. , 2013, The Journal of clinical endocrinology and metabolism.

[44]  S. Mudaliar,et al.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. , 2013, The Journal of clinical endocrinology and metabolism.

[45]  J. Pickard,et al.  A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. , 2013, The Journal of clinical endocrinology and metabolism.

[46]  L. Aaltonen,et al.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. , 2013, Endocrine reviews.

[47]  S. Gultekin,et al.  Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience , 2013, Pituitary.

[48]  Adam N. Mamelak,et al.  Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases , 2013, Pituitary.

[49]  A. Barkan,et al.  The changing face of acromegaly—advances in diagnosis and treatment , 2012, Nature Reviews Endocrinology.

[50]  Nicholas F. Marko,et al.  Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. , 2012, Journal of neurosurgery.

[51]  J. Ramm-Pettersen,et al.  Intensity of pituitary adenoma on T2‐weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly , 2012, Clinical endocrinology.

[52]  A. Vortmeyer,et al.  Somatic GNAS Mutation Causes Widespread and Diffuse Pituitary Disease in Acromegalic Patients with McCune-Albright Syndrome , 2012, The Journal of clinical endocrinology and metabolism.

[53]  Eun Jig Lee,et al.  Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. , 2012, Neurosurgery.

[54]  V. Torri,et al.  Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly , 2012, PloS one.

[55]  Tzulip Phang,et al.  Clinical implications of growth hormone–secreting tumor subtypes , 2012, Endocrine.

[56]  J. Ayuk.  Does pituitary radiotherapy increase the risk of stroke and, if so, what preventative actions should be taken? , 2012, Clinical endocrinology.

[57]  M. Buchfelder,et al.  Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. , 2012, The Journal of clinical endocrinology and metabolism.

[58]  P. Chanson,et al.  Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. , 2012, The Journal of clinical endocrinology and metabolism.

[59]  W. Drake,et al.  Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. , 2012, The Journal of clinical endocrinology and metabolism.

[60]  J. Bollerslev,et al.  Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly , 2012, Clinical endocrinology.

[61]  M. Bidlingmaier,et al.  Elevated incidence of sleep apnoea in acromegaly—correlation to disease activity , 2012, Sleep and Breathing.

[62]  M. Gadelha,et al.  Aortic root ectasia in patients with acromegaly: experience at a single center , 2011, Clinical endocrinology.

[63]  E. Laws,et al.  Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. , 2011, The Journal of clinical endocrinology and metabolism.

[64]  H. Orskov,et al.  Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. , 2011, The Journal of clinical endocrinology and metabolism.

[65]  S. Melmed,et al.  Clinical, quality of life, and economic value of acromegaly disease control , 2011, Pituitary.

[66]  S. Melmed.  Pathogenesis of pituitary tumors , 2011, Nature Reviews Endocrinology.

[67]  Rolf P. Würtz,et al.  A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. , 2011, The Journal of clinical endocrinology and metabolism.

[68]  T. Schwartz,et al.  Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. , 2011, Neurosurgical focus.

[69]  P. Chanson,et al.  Place of cabergoline in acromegaly: a meta-analysis. , 2011, The Journal of clinical endocrinology and metabolism.

[70]  B. Gómez-Anson,et al.  Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. , 2010, The Journal of clinical endocrinology and metabolism.

[71]  L. Katznelson.  Approach to the patient with persistent acromegaly after pituitary surgery. , 2010, The Journal of clinical endocrinology and metabolism.

[72]  S. Moebus,et al.  Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. , 2010, The Journal of clinical endocrinology and metabolism.

[73]  P. Stewart,et al.  Mortality in patients with pituitary disease. , 2010, Endocrine reviews.

[74]  D. Hommes,et al.  Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. , 2010, The Journal of clinical endocrinology and metabolism.

[75]  S. Melmed,et al.  Pituitary somatostatin receptor signaling , 2010, Trends in Endocrinology & Metabolism.

[76]  Jeffrey N Bruce,et al.  Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under‐recognized and under‐diagnosed , 2010, Clinical endocrinology.

[77]  Michael Buchfelder,et al.  Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. , 2010, The Journal of clinical endocrinology and metabolism.

[78]  P. Chanson,et al.  Endocrine aspects of obstructive sleep apnea. , 2010, The Journal of clinical endocrinology and metabolism.

[79]  A. Ben-Shlomo.  Pituitary gland: Predictors of acromegaly-associated mortality , 2010, Nature Reviews Endocrinology.

[80]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[81]  R. Clayton,et al.  ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[82]  A. Colao,et al.  Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. , 2009, The Journal of clinical endocrinology and metabolism.

[83]  S. Heymsfield,et al.  Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry. , 2009, The Journal of clinical endocrinology and metabolism.

[84]  A. Colao,et al.  Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegaly , 2009, Clinical endocrinology.

[85]  D. Russell-Jones,et al.  Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[86]  R. Clayton,et al.  Monitoring disease activity using GH and IGF‐I in the follow‐up of 501 patients with acromegaly , 2009, Clinical endocrinology.

[87]  W. Drake,et al.  Long‐term experience of pegvisomant therapy as a treatment for acromegaly , 2009, Clinical endocrinology.

[88]  K. McDonald,et al.  Familial pituitary tumor syndromes , 2009, Nature Reviews Endocrinology.

[89]  I. Morange,et al.  Lanreotide for the treatment of acromegaly , 2009, Advances in therapy.

[90]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[91]  P. Cappabianca,et al.  Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre study , 2009, Clinical endocrinology.

[92]  R. Clayton,et al.  Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. , 2009, The Journal of clinical endocrinology and metabolism.

[93]  P. Chanson,et al.  Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. , 2009, The Journal of clinical endocrinology and metabolism.

[94]  A. J. van der Lely,et al.  Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. , 2009, European journal of endocrinology.

[95]  S. Nonogaki,et al.  Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment , 2009, Pituitary.

[96]  J. Romijn,et al.  High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. , 2009, European journal of endocrinology.

[97]  C. Yedinak,et al.  Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. , 2009, Journal of neurosurgery.

[98]  S. Melmed,et al.  The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[99]  F. Minuto,et al.  Computed tomography colonography in acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[100]  M. Bidlingmaier.  Problems with GH assays and strategies toward standardization. , 2008, European journal of endocrinology.

[101]  K. Kovacs,et al.  p21Cip1 restrains pituitary tumor growth , 2008, Proceedings of the National Academy of Sciences.

[102]  M. Davi’,et al.  Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. , 2008, European journal of endocrinology.

[103]  G. Vargas,et al.  Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[104]  S. Melmed,et al.  Lipodystrophy in patients with acromegaly receiving pegvisomant. , 2008, The Journal of clinical endocrinology and metabolism.

[105]  G. Gamble,et al.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. , 2008, European journal of endocrinology.

[106]  B. Degnan,et al.  Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. , 2008, The Journal of clinical endocrinology and metabolism.

[107]  R. Murray,et al.  A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[108]  J. Hald,et al.  Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. , 2008, The Journal of clinical endocrinology and metabolism.

[109]  I. Login,et al.  Governor Pio Pico, the monster of California…no more: lessons in neuroendocrinology , 2008, Pituitary.

[110]  A. Franzin,et al.  The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. , 2008, The Journal of clinical endocrinology and metabolism.

[111]  F. Esposito,et al.  Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. , 2008, The Journal of clinical endocrinology and metabolism.

[112]  P. Chanson,et al.  Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. , 2008, Endocrinology.

[113]  Hang Lee,et al.  Changing patterns in diagnosis and therapy of acromegaly over two decades. , 2008, The Journal of clinical endocrinology and metabolism.

[114]  N. Karavitaki,et al.  Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide , 2008, Clinical endocrinology.

[115]  Julian R. E. Davis,et al.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[116]  Ton de Jong,et al.  Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. , 2008, The Journal of clinical endocrinology and metabolism.

[117]  J. Hald,et al.  The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma , 2008, Clinical endocrinology.

[118]  S. Grottoli,et al.  Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor. , 2008, The Journal of clinical endocrinology and metabolism.

[119]  A. Barkan,et al.  Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. , 2008, The Journal of clinical endocrinology and metabolism.

[120]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[121]  C. Spinelli,et al.  Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. , 2007, The Journal of clinical endocrinology and metabolism.

[122]  P. Brown,et al.  Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. , 2007, Journal of neurosurgery.

[123]  M. Bronstein,et al.  Does partial surgical tumour removal influence the response to octreotide‐LAR in acromegalic patients previously resistant to the somatostatin analogue? , 2007, Clinical endocrinology.

[124]  P. Caron,et al.  Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa , 2007, Clinical endocrinology.

[125]  G. Wieringa,et al.  Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice , 2007, Clinical endocrinology.

[126]  J. Romijn,et al.  Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients , 2007, Pituitary.

[127]  A. Parodi,et al.  Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. , 2007, The Journal of clinical endocrinology and metabolism.

[128]  A. Umpleby,et al.  Protein metabolism in acromegaly: differential effects of short- and long-term treatment. , 2007, The Journal of clinical endocrinology and metabolism.

[129]  Jan Lubinski,et al.  Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations , 2007, Proceedings of the National Academy of Sciences.

[130]  W. Haverkamp,et al.  Dopamine agonists and the risk of cardiac-valve regurgitation. , 2007, The New England journal of medicine.

[131]  M. Buchfelder,et al.  Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. , 2007, European journal of endocrinology.

[132]  S. Melmed.  Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[133]  S. Staugaitis,et al.  Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[134]  A. Beckers,et al.  High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.

[135]  H. Höfler,et al.  Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans , 2006, Proceedings of the National Academy of Sciences.

[136]  G. Romanello,et al.  Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. , 2006, The Journal of clinical endocrinology and metabolism.

[137]  B. Scheithauer,et al.  Pathobiology of Pituitary Adenomas and Carcinomas , 2006, Neurosurgery.

[138]  D. Clemmons.  Clinical utility of measurements of insulin-like growth factor 1 , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[139]  S. Melmed,et al.  Skin manifestations in acromegaly. , 2006, Clinics in dermatology.

[140]  G. Lasio,et al.  Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. , 2006, The Journal of clinical endocrinology and metabolism.

[141]  A. Baccarelli,et al.  Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. , 2006, The Journal of clinical endocrinology and metabolism.

[142]  L. Cavallo,et al.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. , 2006, The Journal of clinical endocrinology and metabolism.

[143]  J. Frystyk,et al.  Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. , 2005, The Journal of clinical endocrinology and metabolism.

[144]  M. Vance,et al.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. , 2005, The Journal of clinical endocrinology and metabolism.

[145]  E. Laws,et al.  Perioperative Management of Patients Undergoing Transsphenoidal Pituitary Surgery , 2005, Anesthesia and analgesia.

[146]  A. Bianchi,et al.  Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross‐Sectional Study in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[147]  P. Chanson,et al.  Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. , 2005, The Journal of clinical endocrinology and metabolism.

[148]  D. Rabinowitz,et al.  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[149]  P. Chanson,et al.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[150]  Kolja A. Wawrowsky,et al.  Somatostatin Receptor Type 5 Modulates Somatostatin Receptor Type 2 Regulation of Adrenocorticotropin Secretion* , 2005, Journal of Biological Chemistry.

[151]  A. Barkan,et al.  Clinically silent somatotropinomas may be biochemically active. , 2005, The Journal of clinical endocrinology and metabolism.

[152]  D. Leroith,et al.  Intact insulin and insulin-like growth factor-I receptor signaling is required for growth hormone effects on skeletal muscle growth and function in vivo. , 2005, Endocrinology.

[153]  D. Rubello,et al.  Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. , 2005, The Journal of clinical endocrinology and metabolism.

[154]  J. Bevan.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[155]  S. Asa,et al.  The 2004 World Health Organization classification of pituitary tumors: What is new? , 2005, Acta Neuropathologica.

[156]  M. Brada,et al.  Radiosurgery for pituitary adenomas , 2004, Clinical endocrinology.

[157]  K. Mann,et al.  Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. , 2004, European journal of endocrinology.

[158]  A. Tabarin,et al.  One‐year follow‐up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel® , 2004, Clinical endocrinology.

[159]  F. Dekker,et al.  Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. , 2004, The Journal of clinical endocrinology and metabolism.

[160]  R. Clayton,et al.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[161]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[162]  P. Freda,et al.  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. , 2004, The Journal of clinical endocrinology and metabolism.

[163]  M. Fischler,et al.  Using the Intubating Laryngeal Mask Airway for Ventilation and Endotracheal Intubation in Anesthetized and Unparalyzed Acromegalic Patients , 2004, Journal of neurosurgical anesthesiology.

[164]  M. Korbonits,et al.  Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. , 2002, European journal of endocrinology.

[165]  Jeroen J. Bax,et al.  Increased prevalence of regurgitant valvular heart disease in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[166]  J. Bruce,et al.  Basal and Glucose-Suppressed GH Levels Less Than 1 μg/L in Newly Diagnosed Acromegaly , 2004, Pituitary.

[167]  I. Lancranjan,et al.  Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients , 2004, Pituitary.

[168]  R. Osamura,et al.  Immunohistochemical colocalization of growth hormone (GH) and α subunit in human GH secreting pituitary adenomas , 2004, Virchows Archiv A.

[169]  N. Halmi.  Occurrence of both growth hormone- and prolactin-immunoreactive material in the cells of human somatotropic pituitary adenomas containing Mammotropic elements , 2004, Virchows Archiv A.

[170]  J. Bilbao,et al.  Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegaly , 2004, Acta Neuropathologica.

[171]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[172]  Christian Bruns,et al.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.

[173]  D. Roith.  The Insulin-Like Growth Factor System , 2003, Experimental Diabesity Research.

[174]  G. Lasio,et al.  Estroprogestinic pill normalizes IGF-I levels in acromegalic women , 2003, Journal of endocrinological investigation.

[175]  F. Trimarchi,et al.  Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. , 2003, European journal of endocrinology.

[176]  A. Barkan,et al.  Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. , 2002, The Journal of clinical endocrinology and metabolism.

[177]  H. Machado,et al.  Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? , 2002, The Journal of clinical endocrinology and metabolism.

[178]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.

[179]  M. Vance,et al.  Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. , 2001, The Journal of clinical endocrinology and metabolism.

[180]  D. Le Roith,et al.  Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. , 2001, Annual review of physiology.

[181]  J. Bertherat,et al.  Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. , 2000, The Journal of clinical endocrinology and metabolism.

[182]  A. Renehan,et al.  The prevalence and characteristics of colorectal neoplasia in acromegaly. , 2000, The Journal of clinical endocrinology and metabolism.

[183]  R. Reznek,et al.  The Pathology of Median Neuropathy in Acromegaly , 2000, Annals of Internal Medicine.

[184]  F. Roelfsema,et al.  Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. , 2000, The Journal of clinical endocrinology and metabolism.

[185]  P. Lichter,et al.  Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. , 2000, The New England journal of medicine.

[186]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[187]  S. Melmed,et al.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis , 1999, Nature Medicine.

[188]  J. J. Mukherjee,et al.  Menstrual irregularity in women with acromegaly. , 1999, The Journal of clinical endocrinology and metabolism.

[189]  M. Kirschner,et al.  Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. , 1999, Science.

[190]  P. Marzullo,et al.  Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. , 1999, The Journal of clinical endocrinology and metabolism.

[191]  E. Duncan,et al.  Investigation protocol: Acromegaly and its investigation , 1999, Clinical endocrinology.

[192]  M. Salvatore,et al.  Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. , 1999, The Journal of clinical endocrinology and metabolism.

[193]  S. Wardlaw,et al.  Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. , 1998, Journal of neurosurgery.

[194]  S. Melmed,et al.  Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. , 1998, The Journal of clinical endocrinology and metabolism.

[195]  P. Marzullo,et al.  Reversibility of joint thickening in acromegalic patients: an ultrasonography study. , 1998, The Journal of clinical endocrinology and metabolism.

[196]  S. Ezzat,et al.  Psychological Features of Acromegaly , 1998, Psychotherapy and Psychosomatics.

[197]  P. Marzullo,et al.  Prostatic hyperplasia: an unknown feature of acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[198]  A. DeSalles,et al.  Multiple radiation-induced intracranial lesions after treatment for pituitary adenoma. Case report. , 1998, Journal of neurosurgery.

[199]  S. Melmed,et al.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. , 1997, The Journal of clinical investigation.

[200]  I. Chiodini,et al.  Skeletal Involvement in Female Acromegalic Subjects: The Effects of Growth Hormone Excess in Amenorrheal and Menstruating Patients , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[201]  N. Ghannam,et al.  An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. , 1997, The Journal of clinical endocrinology and metabolism.

[202]  P. Marzullo,et al.  Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly , 1997, Clinical endocrinology.

[203]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[204]  A. Ragin,et al.  Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. , 1997, Neurosurgery.

[205]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[206]  I. Lancranjan,et al.  Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. , 1996, Metabolism: clinical and experimental.

[207]  G. Romanelli,et al.  Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. , 1995, The American journal of cardiology.

[208]  C. Sullivan,et al.  Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. , 1994, American journal of respiratory and critical care medicine.

[209]  W. Young,et al.  Octreotide treatment of acromegaly. A randomized, multicenter study. , 1992, Annals of internal medicine.

[210]  S. Asa,et al.  Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. , 1992, Endocrinology.

[211]  D. London,et al.  Growth hormone secreting pituitary carcinoma: a case report and literature review , 1992, Clinical endocrinology.

[212]  J. Bliss,et al.  Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. , 1992, BMJ.

[213]  S. Mather,et al.  Pituitary imaging using a labelled somatostatin analogue in acromegaly , 1992, Clinical endocrinology.

[214]  M. Merino,et al.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. , 1991, The New England journal of medicine.

[215]  J. Pascual,et al.  Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report , 1991, Pain.

[216]  J. Fraumeni,et al.  Acromegaly and gastrointestinal cancer , 1991, Cancer.

[217]  N. Spry,et al.  Blindness in patients after external beam irradiation for pituitary adenomas: two cases occurring after small daily fractional doses. , 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

[218]  P. Sawchenko,et al.  Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant , 1991, Nature.

[219]  F. Bloom,et al.  Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene , 1991, Nature.

[220]  G. Gamble,et al.  The acromegalic rosary , 1991, The Lancet.

[221]  P. Chanson,et al.  Cardiovascular effects of the somatostatin analog octreotide in acromegaly. , 1990, Annals of internal medicine.

[222]  K. Kovacs,et al.  Clonal origin of pituitary adenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[223]  J. E. MacSweeney,et al.  Heel pad thickness is an insensitive index of biochemical remission in acromegaly. , 1990, Clinical radiology.

[224]  S. Asa,et al.  Gigantism due to pituitary mammosomatotroph hyperplasia. , 1990, The New England journal of medicine.

[225]  T. Wagner,et al.  Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[226]  A. Hoffman,et al.  Sequelae to Acromegaly: Reversibility with Treatment of the Primary Disease , 1990, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[227]  M. Vance,et al.  Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. , 1990, The Journal of clinical endocrinology and metabolism.

[228]  L. Lazarus,et al.  Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. , 1990, Annals of internal medicine.

[229]  A. Barkan,et al.  Increased growth hormone pulse frequency in acromegaly. , 1989, The Journal of clinical endocrinology and metabolism.

[230]  S. Asa,et al.  Adenohypophysial changes in mice transgenic for human growth hormone-releasing factor: a histological, immunocytochemical, and electron microscopic investigation. , 1989, Endocrinology.

[231]  T. Sano,et al.  Pituitary cells producing more than one hormone human pituitary adenomas , 1989, Trends in Endocrinology & Metabolism.

[232]  S. Chernausek,et al.  Acromegaloid patients with type A insulin resistance: parallel defects in insulin and insulin-like growth factor-I receptors and biological responses in cultured fibroblasts. , 1989, The Journal of clinical endocrinology and metabolism.

[233]  M. Vance,et al.  Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. , 1989, The Journal of clinical endocrinology and metabolism.

[234]  K. Yoshinaga,et al.  Multiple forms of immunoreactive growth hormone-releasing hormone in human plasma, hypothalamus, and tumor tissues. , 1989, The Journal of clinical endocrinology and metabolism.

[235]  E. Canalis,et al.  Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. , 1989, Endocrinology.

[236]  R. Palmiter,et al.  Growth enhancement of transgenic mice expressing human insulin-like growth factor I. , 1988, Endocrinology.

[237]  S. Lamberts.  The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. , 1988, Endocrine reviews.

[238]  A. Barkan,et al.  Acromegalic arthropathy. Characteristics and response to therapy. , 1988, Arthritis and rheumatism.

[239]  T. Sano,et al.  Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. , 1988, Endocrine reviews.

[240]  G. Braunstein,et al.  Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. , 1988, The Journal of clinical endocrinology and metabolism.

[241]  S. Asa,et al.  Reversible sellar enlargement due to growth hormone‐releasing hormone production by pancreatic endocrine tumors in an acromegalic patient with multiple endocrine neoplasia type I syndrome , 1988, Cancer.

[242]  A. Barkan,et al.  Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. , 1988, The Journal of clinical endocrinology and metabolism.

[243]  R. Hammer,et al.  Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. , 1988, Molecular endocrinology.

[244]  E. Froesch,et al.  Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[245]  K. Alberti,et al.  Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. , 1988, The Journal of clinical investigation.

[246]  W. Vale,et al.  Acromegaly from ectopic growth hormone‐releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long‐acting somatostatin analogue SMS 201–995 , 1988, Cancer.

[247]  G. Giannattasio,et al.  Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas , 1987, Nature.

[248]  R. Hammer,et al.  Growth allometry of the organs in giant transgenic mice. , 1987, Endocrinology.

[249]  T. Sano,et al.  Growth hormone-releasing hormone (GHRH)-secreting pancreatic tumor in a patient with multiple endocrine neoplasia type I. , 1987, The American journal of surgical pathology.

[250]  A. Rogol,et al.  Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. , 1987, The Journal of clinical endocrinology and metabolism.

[251]  L. Swanson,et al.  Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[252]  S. Melmed,et al.  Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. , 1986, The Journal of clinical endocrinology and metabolism.

[253]  K. Kovacs,et al.  Ectopic Pituitary Adenomas with Normal Anterior Pituitary Glands , 1986, The American journal of surgical pathology.

[254]  J. Jansson,et al.  Growth hormone-releasing hormone. , 1986, Endocrine reviews.

[255]  S. Lamberts,et al.  A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. , 1986, The Journal of clinical endocrinology and metabolism.

[256]  H. Wolfe,et al.  Immunocytochemical demonstration of growth hormone-releasing factor in gastrointestinal and pancreatic endocrine tumors. , 1986, American journal of clinical pathology.

[257]  S. Asa,et al.  Immunohistological localization of growth hormone-releasing hormone in human tumors. , 1985, The Journal of clinical endocrinology and metabolism.

[258]  K. Kovacs,et al.  Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. , 1985, The New England journal of medicine.

[259]  D. Bostwick,et al.  Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: characterization and quantification of plasma and tumor human growth hormone-releasing factor. , 1984, The Journal of clinical endocrinology and metabolism.

[260]  J. Vaughan,et al.  Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: plasma GRF levels in 177 acromegalic patients. , 1984, The Journal of clinical endocrinology and metabolism.

[261]  J. Beyer,et al.  LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY , 1984, The Lancet.

[262]  B. Scheithauer,et al.  A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. , 1984, The Journal of clinical endocrinology and metabolism.

[263]  T. Yamaji,et al.  Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. , 1984, The Journal of clinical investigation.

[264]  N. Bersch,et al.  A unique growth factor in patients with acromegaloidism. , 1983, The Journal of clinical endocrinology and metabolism.

[265]  G. Braunstein,et al.  Pathophysiology of acromegaly. , 1983, Endocrine reviews.

[266]  I. Klein,et al.  Skin tags: a cutaneous marker for colonic polyps. , 1983, Annals of internal medicine.

[267]  W. Vale,et al.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour , 1982, Nature.

[268]  N. Ling,et al.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. , 1982, Science.

[269]  K. Kovacs,et al.  Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. , 1982, The Journal of clinical investigation.

[270]  J. Wortsman,et al.  Histochemical characterization of the cutaneous involvement of acromegaly. , 1982, Archives of internal medicine.

[271]  B. A. Enoch,et al.  PITUITARY GIGANTISM: A DISABLING CONDITION , 1982, Clinical endocrinology.

[272]  M. Evans,et al.  Growth hormone-like material in normal human tissues. , 1981, The Journal of clinical endocrinology and metabolism.

[273]  B. Corenblum,et al.  Acromegaly with an adenomatous pharyngeal pituitary. , 1980, JAMA.

[274]  D. Appleton,et al.  EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION , 1980, Clinical endocrinology.

[275]  M. Stachura,et al.  Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly. , 1980, The Journal of clinical investigation.

[276]  D. Clemmons,et al.  Evaluation of acromegaly by radioimmunoassay of somatomedin-C. , 1979, The New England journal of medicine.

[277]  A. Frantz,et al.  Ectopic human growth hormone in ovaries and breast cancer. , 1979, The Journal of clinical endocrinology and metabolism.

[278]  L. Rose,et al.  Association of acromegaly and meningiomas. , 1978, JAMA.

[279]  A. Mason,et al.  Long-term treatment of acromegaly with bromocriptine. , 1977, British medical journal.

[280]  M. Davies,et al.  Muscle changes in acromegaly. , 1976, British medical journal.

[281]  B. Corrin,et al.  ACROMEGALY CAUSED BY PULMONARY CARCINOID TUMOURS , 1976, Clinical endocrinology.

[282]  R. Randall,et al.  Median neuropathy (carpal-tunnel syndrome) in acromegaly. A sign of endocrine overactivity. , 1973, Annals of internal medicine.

[283]  L. Davidoff.  STUDIES IN ACROMEGALY III. THE ANAMNESIS AND SYMPTOMATOLOGY IN ONE HUNDRED CASES , 1926 .

[284]  L. Davidoff.  STUDIES IN ACROMEGALY II. HISTORICAL NOTE , 1926 .

[285]  H. Cushing.  III. Partial Hypophysectomy for Acromegaly: With Remarks on the Function of the Hypophysis. , 1909, Annals of surgery.